Arcellx(ACLX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights — Recently released ASH abstracts for the company's Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile — — 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached — — Preliminary results from 58 patie ...